Mylan Facing Antitrust Probe Over EpiPen's Market Power

By Bonnie Eslinger (January 30, 2017, 10:04 PM EST) -- Mylan NV confirmed Monday that it was under investigation by the Federal Trade Commission for practices related to sales of its EpiPen allergy emergency treatment, but said any suggestion the company took "inappropriate or unlawful actions to prevent generic competition is without merit."...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!